IQVIA Holdings (IQV) FY2025 Earnings Quality Report

Grade: F — Debt Coverage and Goodwill Concentration

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Filed 2026-02-17) + Yahoo Finance

Auditor: PricewaterhouseCoopers LLP — Clean opinion (1 critical audit matter: revenue recognition — estimating costs to complete for clinical research services)

One-line verdict: IQVIA's F grade comes from two structural failures — cash of $2.14B covers only 13% of total debt of $15.95B, and goodwill plus intangibles of $21.58B equals 332% of the $6.50B equity base. A third flag (Debt/EBITDA of 4.6x) sits at the watch threshold. Underneath the leverage, the clinical research business is steady: revenue grew 5.9% to $16.31B, operating cash flow was $2.65B, free cash flow was $2.05B, and the M-Score is a clean -2.47. Two secondary watches (AR growth 20% vs revenue 5.9%, and DSO expansion) add nuance but the core story is balance sheet structure, not earnings quality. This is the aftermath of the 2016 Quintiles-IMS merger plus continuing bolt-on M&A.

The Clinical Research Outsourcing Leader

From the 10-K: "IQVIA is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI, advanced analytics, the latest technologies and extensive domain expertise."

The company employs "approximately 93,000 employees in over 100 countries" and operates 304 offices and laboratories worldwide (per Item 2. Properties).

FY2025 revenues of $16.31B broke down across three reportable segments:

From the MD&A: "We delivered solid results in 2025, navigating a year of industry uncertainty resulting from a variety of macroeconomic factors that together slowed customer decision-making. Our Technology & Analytics Solutions business continued its growth trajectory, with revenue increasing 7.6% over 2024. While our Research & Development Solutions segment has been impacted by client cautiousness, we grew full-year revenue 4.3% over 2024, driven by improved growth rates in the second half of the year."

Segment Reorganization Effective January 2026

From the MD&A: "Effective January 1, 2026, we will be updating our segment reporting to align with industry evolution, our updated operating model, and how internal reporting will be provided to the chief operating decision maker. As a result, the Contract Sales & Medical Solutions segment, which has become more closely related operationally to the Technology & Analytics Solutions segment commercial offerings, will be incorporated into the Technology & Analytics Solutions segment, which is renamed Commercial Solutions."

Operating income grew less than 1% on 5.9% revenue growth — margin compression in an environment where clinical trial activity slowed. From the MD&A: "Technology & Analytics Solutions cost of revenues, exclusive of depreciation and amortization" grew 9.5% while revenue grew 7.6%, compressing the segment's gross margin.

Backlog: $34.2B of Remaining Performance Obligations

From the MD&A: "We ended the year with total company remaining performance obligations of approximately $34.2 billion as of December 31, 2025." This backlog provides revenue visibility roughly equal to two years of current sales — a meaningful cushion for a services business.

Cash Flow and Capital Resources

From the MD&A: "We achieved $2,654 million of cash flows from operating activities, and invested $1,714 million, net of cash, to acquire businesses that will strengthen and expand our offerings moving forward, including acquisitions in all three reportable segments."

Acquisition spend of $1.71B was larger than FCF of $2.05B, meaning essentially all of the free cash flow was deployed on M&A. This pattern is confirmed in the balance sheet: goodwill grew from $14.71B to $16.62B (+$1.91B), driven by the acquired businesses.

From the 10-K: "As of December 31, 2025, cash and cash equivalents were $1,980 million and we had $800 million drawn under our $2,000 million revolving credit facility. As of December 31, 2025, we were in compliance with the financial covenants under our debt agreements in all material respects and do not have material uncertainty about ongoing ability to meet the covenants of our credit arrangements."

The 18-Point Screening

Revenue Quality

A2 watch: AR grew from $1.39B to $1.67B (+20.0%) while revenue grew 5.9%. The AR growth directly reflects both: (1) acquisitions that brought AR balances onto the consolidated ledger, and (2) timing of large clinical trial milestone billings, which IQVIA recognizes over time using the cost-based input method (as described in the critical audit matter). A 4-day DSO expansion (33 to 37) is within normal operational variance but trending the wrong direction.

Expense Quality

Gross margin compression of 1.6pp reflects the cost-growth versus revenue-growth imbalance in the T&A segment noted above. This is right at the threshold of a watch flag but the engine judged it as "stable" (within 5pp).

Cash Flow Quality

C4 is the critical fail. $2.14B of cash and short-term investments against $15.95B of total debt = 13% coverage. However, IQVIA has $1.20B remaining available under its $2.00B revolving credit facility (net of the $800M drawn), plus healthy recurring FCF of $2.05B per year. The 13% headline is tight but liquidity is supported by the recurring cash flow profile and covenant compliance.

Balance Sheet

D1 fail: Goodwill of $16.62B plus other intangibles of $4.96B = $21.58B, or 332% of the $6.50B equity base. This is the legacy of the 2016 Quintiles-IMS merger that created IQVIA, plus successive M&A layers on top.

D2 watch: Debt/EBITDA of 4.6x sits above the engine's 4x threshold but interest coverage is comfortable. EBITDA of $3.46B comfortably exceeds interest expense.

M&A Risk

E2 is close to the line: goodwill plus intangibles grew 12% YoY, below the 30% "surge" threshold but indicative of active M&A deployment. The $1.71B net acquisition spend in FY2025 represents continuing consolidation of the services market.

Beneish M-Score

Key Risks from Item 1A

1. Contract loss and delay risk (first-listed risk). From the 10-K: "The potential loss or delay of contracts could adversely affect our results." Clinical research contracts are cancellable by sponsors, and delayed enrollment or client-requested pauses directly impact revenue recognition timing.

2. Pricing and cost overrun risk. "Our financial results may be adversely affected if we underprice our contracts, overrun our cost estimates or fail to receive approval for or experience delays in documenting change orders." This connects directly to the critical audit matter — IQVIA uses cost-based input method for recognizing RDS revenue, so cost estimation errors feed straight into revenue.

3. Client concentration and therapeutic concentration. "We may be adversely affected by client or therapeutic concentration." A shift in biopharmaceutical R&D priorities or consolidation among clients (pharma M&A) can reduce the addressable market.

4. Client cautiousness in the current environment. The MD&A explicitly acknowledged this: "Research & Development Solutions segment has been impacted by client cautiousness." The 10-K ties this to macroeconomic factors and slowed decision-making.

5. Debt covenants and leverage restrictions. From the 10-K risk factors: "Restrictions imposed in the Senior Secured Credit Facilities (as defined below) and other outstanding indebtedness, including the indentures governing outstanding notes." IQVIA's $15.95B debt load comes with covenant restrictions that limit capital allocation flexibility.

6. Revenue recognition cost estimation (the critical audit matter). From PwC's opinion: "revenue of the Research & Development Solutions segment for the year ended December 31, 2025, is $8,896 million, the majority of which relates to service contracts for clinical research that represent a single performance obligation. The Company recognized revenue for these contracts over time using a cost-based input method. Revenue was recognized based on progress on the performance obligation, which was measured by the proportion of actual costs incurred to the total costs expected to complete the contract." The CAM designation reflects that PwC had to "test management's process for determining the estimate of total costs to complete for a sample of clinical research contracts by evaluating the reasonableness of significant assumptions made by management related to direct labor and third-party costs."

7. IT systems and information security. "IT systems and Information Security breaches and unauthorized use of our IT systems and information could expose us, our clients, our data suppliers or others to risk of loss." Given IQVIA handles sensitive patient and clinical trial data at massive scale, cyber risk is a first-order concern.

Altman Z-Score and F-Score

Z-Score of 1.16 sits just inside the grey zone — driven by the high debt-to-asset ratio. The F-Score of 1.76 is below the 2.45 threshold where misstatement probability becomes elevated.

Summary

Grade: F. Two fails (Cash vs Debt, Goodwill+Intangibles) plus two watches (AR vs revenue, Leverage) reflect the accumulated balance sheet effect of M&A.

IQVIA's F grade traces to a decade of consolidation: the 2016 merger that created the company, and the continued bolt-on M&A strategy that deployed $1.71B on acquisitions in FY2025 alone. The result is a balance sheet where $21.58B of goodwill and intangibles sit on top of $6.50B of equity (332%), cash of $2.14B covers just 13% of $15.95B of debt, and Debt/EBITDA is 4.6x.

The operational story is steadier than the balance sheet suggests: $16.31B of revenue with 5.9% growth, $2.65B of operating cash flow, $2.05B of free cash flow, and a $34.2B remaining-performance-obligation backlog that provides two years of revenue visibility. Gross margin compression of 1.6pp signals modest cost pressure, and PwC's critical audit matter highlights the estimation risk in the cost-based revenue recognition model for the $8.9B Research & Development Solutions segment.

The M-Score of -2.47 and accruals ratio of -4.3% indicate no earnings manipulation pattern. The risk is the compounding effect of leverage plus cyclical softness in biopharma R&D spending — if FCF contracts while debt matures, the covenant buffer narrows.

**Disclaimer**: This report is based on IQVIA's FY2025 10-K (SEC EDGAR) and public financial data. This is NOT investment advice.

Data: SEC EDGAR 10-K (Filed 2026-02-17) + Yahoo Finance

Auditor: PricewaterhouseCoopers LLP (Unqualified opinion, 1 critical audit matter)